摘要:
A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by using the antibody alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein. More specifically, an anti-cancer drug is obtained by using an antibody, in which variable region of its heavy chain comprises the amino acid sequence of SEQ ID NO: 115 and variable region of the light chain comprises the amino acid sequence of SEQ ID NO: 117, alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein.
摘要翻译:通过将衍生自癌症患者的癌症组织的淋巴细胞与小鼠骨髓瘤细胞融合获得的杂交瘤产生特异性识别癌细胞例如非小细胞肺癌,胰腺癌和胃癌细胞的新型人单克隆抗体。 通过单独使用抗体或将抗体锚定在包含毒素或其中的抗癌药物的脂质体的表面上来获得抗癌药物。 更具体地,通过使用抗体,其重链的可变区包含SEQ ID NO:115的氨基酸序列并且轻链的可变区包含SEQ ID NO的氨基酸序列 :117单独或将抗体锚定在包含其中的毒素或抗癌药物的脂质体的表面上。
摘要:
A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by using the antibody alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein. More specifically, an anti-cancer drug is obtained by using an antibody, in which variable region of its heavy chain comprises the amino acid sequence of SEQ ID NO: 115 and variable region of the light chain comprises the amino acid sequence of SEQ ID NO: 117, alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein.
摘要翻译:通过将衍生自癌症患者的癌症组织的淋巴细胞与小鼠骨髓瘤细胞融合获得的杂交瘤产生特异性识别癌细胞例如非小细胞肺癌,胰腺癌和胃癌细胞的新型人单克隆抗体。 通过单独使用抗体或将抗体锚定在包含毒素或其中的抗癌药物的脂质体的表面上来获得抗癌药物。 更具体地,通过使用抗体,其重链的可变区包含SEQ ID NO:115的氨基酸序列并且轻链的可变区包含SEQ ID NO的氨基酸序列 :117单独或将抗体锚定在包含其中的毒素或抗癌药物的脂质体的表面上。
摘要:
Disclosed is a monoclonal antibody which has a heavy chain variable region containing amino acid sequences depicted in SEQ ID NOs:74, 76 and 78 and a light chain variable region containing amino acid sequences depicted in SEQ ID NOs:80, 82 and 84. The monoclonal antibody can be used as a cancer therapeutic agent which acts selectively on a cancer tissue of non-small lung cancer, pancreatic cancer, gastric cancer or the like.
摘要翻译:公开了具有包含SEQ ID NO:74,76和78所示的氨基酸序列的重链可变区和含有SEQ ID NO:80,82和84所示氨基酸序列的轻链可变区的单克隆抗体。 单克隆抗体可以用作非选择性地作用于非小细胞肺癌,胰腺癌,胃癌等癌症组织的癌症治疗剂。